ArticleFrontiers in oncology2026
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the characteristics and functional status of the lymphocyte-activation gene-3 (LAG-3), cluster of differentiation 8 (CD8), programmed cell death protein-1 (PD-1) immune microenvironment in tumor tissues of hepatocellular carcinoma (HCC) patients and evaluate their value as prognostic biomarkers for the efficacy of combination of anti-PD-1 antibodies with Lenvatinib. Patients and methods: This retrospective study collected clinical data from 77 patients with hepatocellular carcinoma who received Lenvatinib plus anti-PD-1 antibodies at the Department of Oncology, Nanjing Drum Tower Hospital between January 2018 and June 2023. Following combination therapy with Lenvatinib and anti-PD-1 antibodies, 1 patient achieved complete response (CR), 23 achieved partial response (PR), 39 achieved stable disease (SD), and 14 achieved progressive disease (PD). Results: Age stratification (<60 years vs ≥60 years), cirrhosis status, and Conclusion: Our study proposes that LAG-3 serves as a potential prognostic factor for identifying survival benefits from Lenvatinib plus anti-PD-1 antibodies in hepatocellular carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.